Company
Fate Therapeutics
Fate Therapeutics has 18 drugs tracked on RxWires: 2 in Phase 2, 2 in Phase 1/2, 14 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| ProHema-CB | Phase 2 | Hematologic Malignancies |
| FT819 | Phase 2 | Lupus Nephritis |
| ProTmune | Phase 1/2 | Hematologic Malignancies |
| FT839 | Phase 1/2 | ANCA-Associated Vasculitis (AAV) |
| FT596 | Phase 1 | Diffuse Large B Cell Lymphoma |
| FT538 | Phase 1 | Acute Myeloid Leukemia |
| Fludarabine | Phase 1 | Hematologic Malignancies |
| FT576 (Allogenic CAR NK cells with BCMA expression) | Phase 1 | Multiple Myeloma |
| FT516 | Phase 1 | Acute Myelogenous Leukemia |
| FT500 | Phase 1 | Advanced Solid Tumors |
| Biological: ProHema-CB | Phase 1 | Hematologic Malignancies |
| FT836 | Phase 1 | Non-Small Cell Lung Cancer |
| ProHema-CB Transplant | Phase 1 | Metabolic Disorders |
| FT825 | Phase 1 | Advanced Solid Tumor |
| FT536 | Phase 1 | Non Small Cell Lung Cancer |
| Single FT1050 treated UCB unit | Phase 1 | Non-Hodgkin's Lymphoma (NHL) |
| FATE-NK100 | Phase 1 | HER2 Positive Gastric Cancer |
| FT522 | Phase 1 | Relapsed/Refractory B-Cell Lymphoma |
Latest
- fate therapeutics filed 8-K
- fate therapeutics filed 8-K
- fate therapeutics filed 8-K
- fate therapeutics filed 8-K
- fate therapeutics filed 8-K
Follow Fate Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.